Endothelial Function and Cardiovascular Disease: Advances and Challenges

Dear Colleagues,

In recent years, due to the emergence of RNA sequencing (RNA-Seq), single-cell RNA-seq, secretome profiling, lipidomics, metabolomics, etc., great strides have been made in our understanding of the important role of endothelial dysfunction in various types of cardiovascular disease (CVD). These biotechnological advances enable us to decipher the heterogeneity of endothelial cells, smooth muscle cells and immune cells and unravel their unique roles in CVD, as well as assisting in the discovery of novel biomarkers of CVD. Beyond traditional lipid-lowering therapies such as statins exerting pleiotropic effects on endothelial cells, anti-inflammatory therapies with anti-interleukin 1 beta, colchicine and anti-interleukin 6 have marked the concept of “anti-inflammation therapy in atherosclerosis” as a reality. These anti-inflammatory therapies prevent CVD partially via preventing endothelial dysfunction. Endothelial cells safeguard vascular health by secreting vasoactive molecules, including nitric oxide, to maintain the vascular tone and anti-thrombotic interface. Once they have become dysfunctional, endothelial cells lose their capacity to maintain vascular homeostasis, leading to augmented inflammation, oxidative stress, constriction, leukocyte adhesion, endothelial–mesenchymal transition and senescence. Targeted therapies against these aspects of endothelial dysfunction hold promise for treating CVD. This Special Issue is devoted to the use of advanced technologies to understand the pathomechanisms of endothelial dysfunction in CVD, and to the discovery of novel targeted therapies. Topics of interest include, but are not limited to, new therapeutic targets in endothelial dysfunction, nutraceuticals in preventing endothelial dysfunction and novel biomarkers of endothelial dysfunction. Preclinical, clinical and translational studies related to endothelial dysfunction and CVD are welcome for submission to this Special Issue. In addition, experimental and bioinformatics papers and up-to-date review articles related to endothelial function and CVD are also welcome.

Dr. Suowen Xu
Dr. Li Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardiovascular disease
• endothelial (dys)function
• multiomics
• therapies
• inflammation
• mechanobiology
• endothelial homeostasis